UC Berkeley and other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, are accelerating scientific research of psilocybin by launching a new center focusing on the compound (https://ibn.fm/VdvfN). Cybin (NEO: CYBN), a mushroom life science company, is positioned amid this growing research interest that is bringing psilocybin into mainstream. A recent article discussing the company reads, “Dedicated to supporting clinical studies across North America and other regions through strategic academic and institutional partnerships, including the Canadian Centre for Psychedelic Science, Cybin is poised to benefit from the increasing research interest in psilocybin. As an early entrant into a rapidly growing field, Cybin seems well positioned to leverage the growing recognition of psychedelic research leading to eventual public acceptance with the potential to propel the whole industry to the new level.”
To view the full article, visit https://ibn.fm/lzn7g
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.